Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Biotechnology Assets's annualized net income for the quarter that ended in Dec. 2025 was €-2.16 Mil. Biotechnology Assets's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €2.20 Mil. Therefore, Biotechnology Assets's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -98.19%.
The historical rank and industry rank for Biotechnology Assets's Return-on-Tangible-Equity or its related term are showing as below:
XMAD:BST'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -1011.09 Med: -176.37 Max: -85.83
Current: -106.98
During the past 13 years, Biotechnology Assets's highest Return-on-Tangible-Equity was -85.83%. The lowest was -1,011.09%. And the median was -176.37%.
XMAD:BST's Return-on-Tangible-Equity is ranked worse than 74.75% of 1200
companies
in the Biotechnology industry
Industry Median: -42.435
vs XMAD:BST: -106.98
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Biotechnology Assets Return-on-Tangible-Equity Related Terms
Biotechnology Assets Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Biotechnology Assets's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:BST vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Biotechnology Assets's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotechnology Assets Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biotechnology Assets's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Biotechnology Assets's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -98.19% mean?
Biotechnology Assets (XMAD:BST) has a Return-on-Tangible-Equity of -98.19% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Biotechnology Assets and its competitors. According to the industry distribution chart, Biotechnology Assets ranks #897 out of 1200 companies in the Biotechnology industry, placing it in the top 74.7%.
Is Biotechnology Assets' Return-on-Tangible-Equity too high?
Biotechnology Assets' current Return-on-Tangible-Equity is -98.19%. Based on the distribution chart, Biotechnology Assets ranks #897 out of 1200 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Biotechnology Assets has a GF Score™ of 22/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biotechnology Assets' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biotechnology Assets ranks #897 out of 1200 companies for Return-on-Tangible-Equity. This places Biotechnology Assets in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Biotechnology Assets and its competitors. Biotechnology Assets's current Return-on-Tangible-Equity is -98.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotechnology Assets stock overvalued right now?
Based on GuruFocus' analysis, Biotechnology Assets (XMAD:BST) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.30, compared to a current price of €0.23 — trading 23.3% below its estimated fair value. The current Return-on-Tangible-Equity is -98.19%. Biotechnology Assets' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Biotechnology Assets (XMAD:BST), the current Return-on-Tangible-Equity is -98.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biotechnology Assets (XMAD:BST) Overvalued in 2026?
Based on GuruFocus' analysis, Biotechnology Assets stock appears to be undervalued.
The current stock price of €0.23 is trading 23.3% below its estimated GF Value™ of €0.30.
GuruFocus considers Biotechnology Assets to be Modestly Undervalued.
Key valuation signals for XMAD:BST:
Return-on-Tangible-Equity: -98.19%
GF Value™: €0.30 vs. price of €0.23 (23.3% below fair value)
No single metric tells the full story. See the XMAD:BST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.
22GF Score
Get the complete analysis for XMAD:BST
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:BST has been successfully added to your 
